510(k) Summary of Safety and Effectiveness

1. Manufacturer and Contact Information:

Manufacturer

Nissho Nipro Corporation Ltd. 10/2 Moo 8, Bangnomko, Sena Ayutthaya, Thailand 13110

U. S. Distributor

Nipro Medical Corporation 3150 N. W. 107th Avenue

Miami, FL 33172

Contact Information

Richard D. Bliss Jr.

Quality Systems Engineering

510 Stonemont Drive Weston, FL 33326

Telephone: (954) 385-1690

Fax: (954) 385-1256

2. Device Classification Name:

The Gastroenterology Devices Panel has classified Hemodialysis system and accessories as Class II. Reference 21 CFR 876.5820.

3. Intended Use:

The Nipro® Blood Tubing Set for Hemodialysis with Transducer Protector and Priming Set is intended to provide extracorporeal access to the patient's blood during hemodialysis. The compatibility of available configurations is the responsibility of the physician.

4. Device Description and Characteristics

This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of the Safe Medical Devices Act (SMDA) 1990.

The Nipro Blood Tubing Set for hemodialysis with or without Transducer Protector and Priming Set includes arterial and venous dialysis blood tubing (non-implanted blood access device) as described in 21 CFR 876.5820. The blood tubing sets have previously been described in detail as part of Premarket Notification, cleared by the FDA under K001465.

The arterial and venous blood tubing set included in this 510(k) is a modification of the Nipro Blood Tubing Set for hemodialysis with transducer protector and priming set K001465. The modification includes the use of an additional transducer protector known as the Borla Transducer Protector mrketed by Fresenius Medical Care North American which cleared FDA under K000702 as Combilines™ Hemodialysis Blood Tubing Set Transducer Protectors. A copy of the clearance letter is enclosed with this submission.

The devices are packaged together for convenient use during the hemodialysis procedures. There are 13 series of arterial line (A201 - A211 and A213 - A214) and 5 series of venous line (V801 - V805). The packaging configurations are of paired and single sets, with priming sets and transducer protectors.

The various blood set models are being manufactured for application with various models of dialysis machines. The components of the device include tubing, drip chambers, infusion tubing, pressure monitoring lines, ports, clamps and filters which are used to pump blood, retain and capture blood debris, infuse medications or fluids, sample blood, monitor pressure, and make connections to other devices. Materials used for the various components in this device include Polyvinylchloride (PVC), Polyethylene (PE), Polycarbonate (PC), Polypropylene (PP), and Polyoxymethylene (POM), and others. In addition, Polybutylene terephthalate (PBT) is used specifically for the Borla Transducer Protector.

The devices are packaged sterile and labeled for single use only. There is no ability to clean and reuse these devices. They are restricted for sale by or on the order of a physician. The results of biocompatibility data support the equivalence of the predicate devices and include pyrogenicity, acute toxicity, intracutaneous reactivity, hemolysis testing, implantation testing and sterility testing.

Substantial Equivalence 5.

Nipro Medical Corporation considers the modified Nipro Blood Tubing Set for Hemodialysis with Transducer Protector (Borla Transducer Protector) and Priming Set to be substantially equivalent to the existing Nipro Blood Tubing Set for Hemodialysis with Transducer Protector (Medisystems Viraguard Transducer Protector) and Priming Set with regard to intended use, materials, biocompatibility, and overall performance characteristics. The labeling has not changed and is equivalent to the predicate devices in intended use, components and materials.



APR 2 7 2001

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Nipro Medical Corporation c/o Mr. Richard D. Bliss, Jr. Quality Systems Engineering, Inc. 510 Stonemont Drive WESTON FL 33326

Re: K010264

Nipro® Blood Tubing Set with Transducer Protector and Priming Set

Dated: January 26, 2001 Received: January 29, 2001

Regulatory Class: II

21 CFR §876.5820/Procode: 78 FIB and 78 FJK

Dear Mr. Bliss:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours

Daniel G. Schultz, M.D.

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Nipro® Blood Tubing Set with Transducer Protector and Priming

Set

Indications for Use:

The Nipro® Blood Tubing Set with Transducer Protector and Priming Sets are disposable bloodlines intended to provide extracorporeal access to the patient's blood during Hemodialysis. The compatibility of available configurations is the responsibility of the physician in charge.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED.)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use or Over-The-Counter Use (Pre 21 CFR 801.109) (Optional Format 1-2-96)
(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices
510(k) Number 50/0264